Basilea Pharmaceutica: all 59 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult SubjectsRecruitingNCT07881224Phase 1
• A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult SubjectsRecruitingNCT07500181Phase 1
• A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.RecruitingNCT06925321Phase 3
• Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose CombinationRecruitingNCT06733675Phase 1
• Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal InfectionsAvailableNCT06433128
• A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.RecruitingNCT05421858Phase 3
• A Study of Fosmanogepix in Healthy Adult Chinese SubjectsCompletedNCT06961708Phase 1Results posted
• A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of CoproporphyrinCompletedNCT06808646Phase 1Results posted
• Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years)CompletedNCT06665555Phase 1Results posted
• Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of AgeCompletedNCT05856227Phase 3Results posted
• Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric AdenocarcinomaTerminatedNCT04604132Phase 1/2Results posted
• Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare MoldsTerminatedNCT04240886Phase 2Results posted
• An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida AurisCompletedNCT04148287Phase 2Results posted
• Derazantinib and Atezolizumab in Patients With Urothelial CancerCompletedNCT04045613Phase 1/2Results posted
• An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With CandidemiaCompletedNCT03604705Phase 2Results posted
• Ceftobiprole in the Treatment of Pediatric Patients With PneumoniaCompletedNCT03439124Phase 3Results posted
• Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaTerminatedNCT03250299Phase 1Results posted
• Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic CholangiocarcinomaCompletedNCT03230318Phase 2Results posted
• Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus BacteremiaCompletedNCT03138733Phase 3Results posted
• Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT03137173Phase 3Results posted
• Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent GlioblastomaCompletedNCT02895360Phase 1/2Results posted
• Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic AntibioticsTerminatedNCT02527681Phase 1Results posted
• Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade GliomaCompletedNCT02490800Phase 1/2Results posted
• Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic AlterationsCompletedNCT01752920Phase 1/2Results posted
• A Study of Ceftobiprole in Patients With Fever and Neutropenia.TerminatedNCT00529282Phase 3Results posted
• A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.CompletedNCT05582187Phase 1
• Food Effect on Ceftibuten/VNRX-7145 in Healthy ParticipantsCompletedNCT05527834Phase 1
• A Bioequivalence Study of APX001 High-load and Low-load TabletsCompletedNCT05491733Phase 1
• Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal FunctionCompletedNCT05488678Phase 1
• VNRX-7145 Drug-Drug Interaction in Healthy Adult VolunteersCompletedNCT04877379Phase 1
• A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy MalesCompletedNCT04804059Phase 1
• VNRX-5024 Safety and PK in Healthy Adult VolunteersCompletedNCT04314206Phase 1
• VNRX-7145 SAD/MAD Safety and PK in Healthy Adult VolunteersCompletedNCT04243863Phase 1
• A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001CompletedNCT04166669Phase 1
• Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male SubjectsCompletedNCT04098692Phase 1
• Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic AlterationsNo longer availableNCT04087876
• Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and NeutropeniaCompletedNCT03333005Phase 1
• Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered OrallyCompletedNCT02957929Phase 1
• Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy SubjectsCompletedNCT02956499Phase 1
• An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid TumorsCompletedNCT01397929Phase 1/2
• Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal DiseaseCompletedNCT01030731Phase 1
• Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy VolunteersCompletedNCT01026740Phase 1
• A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of AgeCompletedNCT01026636Phase 1
• A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese PatientsCompletedNCT01026558Phase 1
• Effect of Ceftobiprole on Human Intestinal MicrofloraCompletedNCT00965042Phase 1
• Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated PneumoniaTerminatedNCT00771719Phase 1
• Pharmacokinetic Study of the Penetration of Ceftobiprole in the BoneCompletedNCT00771524Phase 1
• Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICUCompletedNCT00770978Phase 1
• Alitretinoin in the Treatment of Chronic Hand EczemaCompletedNCT00519675Phase 3
• Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus BacteremiaWithdrawnNCT00505258Phase 2
• Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing ChemotherapyCompletedNCT00413439Phase 2/3
• Ceftobiprole in the Treatment of Patients With Community-Acquired PneumoniaCompletedNCT00326287Phase 3
• Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand DermatitisCompletedNCT00309621Phase 3
• Ceftobiprole in Hospital Acquired PneumoniaCompletedNCT00229008Phase 3
• Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure InfectionsCompletedNCT00228982Phase 3
• Ceftobiprole in Hospital Acquired PneumoniaCompletedNCT00210964Phase 3
• Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure InfectionsCompletedNCT00210899Phase 3
• Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand DermatitisCompletedNCT00124475Phase 3
• Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand DermatitisCompletedNCT00124436Phase 3

← Basilea Pharmaceutica overview and focus areas